Myricx Bio

Myricx Bio is at the forefront of biotechnology research, dedicated to developing a novel class of Antibody Drug Conjugates (ADCs) for cancer treatment. Focusing on NMT inhibition, Myricx Bio is committed to innovation and the advancement of therapeutic solutions in oncology.

Located in London, at Kings Cross, Myricx Bio leverages cutting-edge research and development to create selective cytotoxic payloads. The company's approach aims to provide more effective and targeted cancer therapies, contributing significantly to the field of biotechnology.

Myricx Bio is dedicated to pushing the boundaries of scientific discovery and improving patient outcomes. We invite the management team at Myricx Bio to enhance this profile further by creating a customized company showcase and product listing on our platform, highlighting the unique aspects of their work.